Sendero Wealth Management LLC Has $2.86 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Sendero Wealth Management LLC increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 20,944 shares of the company’s stock after buying an additional 672 shares during the quarter. Sendero Wealth Management LLC’s holdings in Neurocrine Biosciences were worth $2,859,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Clarus Wealth Advisors acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at about $253,000. Park Avenue Securities LLC raised its position in Neurocrine Biosciences by 23.3% during the fourth quarter. Park Avenue Securities LLC now owns 7,080 shares of the company’s stock valued at $966,000 after acquiring an additional 1,336 shares in the last quarter. Tealwood Asset Management Inc. raised its position in Neurocrine Biosciences by 1.0% during the fourth quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock valued at $1,626,000 after acquiring an additional 118 shares in the last quarter. Pallas Capital Advisors LLC lifted its stake in Neurocrine Biosciences by 19.0% in the fourth quarter. Pallas Capital Advisors LLC now owns 7,673 shares of the company’s stock valued at $1,047,000 after acquiring an additional 1,225 shares during the last quarter. Finally, First Hawaiian Bank grew its position in Neurocrine Biosciences by 21.3% in the fourth quarter. First Hawaiian Bank now owns 12,243 shares of the company’s stock worth $1,671,000 after acquiring an additional 2,150 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 272 shares of the company’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total value of $37,563.20. Following the completion of the transaction, the insider now directly owns 2,507 shares in the company, valued at approximately $346,216.70. This represents a 9.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,694 shares of company stock valued at $479,230 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $142.56 on Thursday. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The stock has a market cap of $14.43 billion, a PE ratio of 38.22 and a beta of 0.33. The firm has a 50-day simple moving average of $131.13 and a 200 day simple moving average of $131.11.

Analysts Set New Price Targets

NBIX has been the topic of a number of recent research reports. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. UBS Group raised their target price on Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Raymond James reiterated an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Barclays increased their price objective on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, December 23rd. Finally, BMO Capital Markets decreased their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.81.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.